Basis for molecular diagnostics and immunotherapy for esophageal cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Basis for molecular diagnostics and immunotherapy for esophageal cancer
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 17, Issue 1, Pages 33-45
Publisher
Informa UK Limited
Online
2016-11-13
DOI
10.1080/14737140.2017.1260449
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapy advances in uro-genital malignancies
- (2016) Raffaele Ratta et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
- (2016) Naoki Takahashi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Innovation in Bladder Cancer Immunotherapy
- (2016) H. Barton Grossman et al. JOURNAL OF IMMUNOTHERAPY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma
- (2016) Charlotta Hedner et al. PLoS One
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
- (2015) B Homet Moreno et al. BRITISH JOURNAL OF CANCER
- The use of combinations of monoclonal antibodies in clinical oncology
- (2015) Linda M. Henricks et al. CANCER TREATMENT REVIEWS
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Animal Models of Barrett's Esophagus and Esophageal Adenocarcinoma-Past, Present, and Future
- (2015) Harit Kapoor et al. CTS-Clinical and Translational Science
- Blinatumomab: a new era of treatment for adult ALL?
- (2015) Xavier Thomas LANCET ONCOLOGY
- Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials
- (2015) Xu Tian et al. MEDICAL ONCOLOGY
- High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
- (2015) Paolo Nuciforo et al. Molecular Oncology
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- (2015) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
- (2015) Edward B. Garon SEMINARS IN ONCOLOGY
- Barrett's esophagus: recent insights into pathogenesis and cellular ontogeny
- (2015) Harit Kapoor et al. Translational Research
- Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
- (2015) Roland F. Schwarz et al. PLOS MEDICINE
- Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.
- (2015) Janghee Woo et al. Gastroenterology Report
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
- (2014) M. Dai et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma
- (2014) Erjian Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects
- (2014) Huan Shi et al. Molecular Cancer
- Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
- (2014) Daniel V.T. Catenacci Molecular Oncology
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- The Prognostic Role of the Class III β-Tubulin in Non-Small Cell Lung Cancer (NSCLC) Patients Receiving the Taxane/Vinorebine-Based Chemotherapy: A Meta-Analysis
- (2014) Yan-Long Yang et al. PLoS One
- Endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal tumors: A meta-analysis
- (2014) Jing Wang WORLD JOURNAL OF GASTROENTEROLOGY
- Vitamin D and the Epidemiology of Upper Gastrointestinal Cancers: A Critical Analysis of the Current Evidence
- (2013) R. Trowbridge et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- βIII-Tubulin: biomarker of taxane resistance or drug target?
- (2013) Roshan Karki et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- 1,25-dihydroxyvitamin D in the pathogenesis of Barrett’s esophagus and esophageal adenocarcinoma
- (2013) Ryan Trowbridge et al. Expert Review of Clinical Immunology
- Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2013) Gerold Bepler et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care
- (2013) Amikar Sehdev et al. Journal of Hematology & Oncology
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
- (2013) Lianhai Zhang et al. Scientific Reports
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma
- (2012) Ryan Trowbridge et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
- (2012) Antoni Ribas et al. Journal of Translational Medicine
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
- (2011) Ming Yin et al. CLINICAL CANCER RESEARCH
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
- (2011) Robert Pirker et al. LANCET ONCOLOGY
- One particle to rule them all?
- (2011) Natalie de Souza NATURE METHODS
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Changing incidence of gastric and oesophageal cancer subtypes in central Switzerland between 1982 and 2007
- (2009) Adrian Schmassmann et al. EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers
- (2008) Ahmad A Tarhini et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
- (2008) Michael S. Braun et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and Age
- (2008) L. M. Brown et al. JNCI-Journal of the National Cancer Institute
- Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
- (2008) Pascal Sève et al. LANCET ONCOLOGY
- Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
- (2007) Beverly A. Teicher BIOCHEMICAL PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started